July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Choroidal Changes after Suprachoroidal Injection of CLS-TA, Triamcinolone Acetonide Injectable Suspension, in Eyes with Macular Edema Secondary to Retinal Vein Occlusion
Author Affiliations & Notes
  • Alex Willoughby
    Ophthalmology, UC Davis , Sacramento, California, United States
  • Vivian Vuong
    Ophthalmology, UC Davis , Sacramento, California, United States
  • David Cunefare
    Duke University Biomedical Engineering, Durham, North Carolina, United States
  • Sina Farsiu
    Duke University Biomedical Engineering, Durham, North Carolina, United States
  • Glenn Noronha
    Clearside Biomedical, Inc., Alpharetta, Georgia, United States
  • Ronald P Danis
    Univ. Wisconsin- Madison, Madison, Wisconsin, United States
  • Glenn Yiu
    Ophthalmology, UC Davis , Sacramento, California, United States
  • Footnotes
    Commercial Relationships   Alex Willoughby, None; Vivian Vuong, None; David Cunefare, None; Sina Farsiu, Farsiu (P); Glenn Noronha, Clearside (E), Clearside (P), Clearside (I); Ronald Danis, EyeKor Inc (E), EyeKor Inc (I); Glenn Yiu, None
  • Footnotes
    Support  Vivian S. Vuong: National Center for Advancing Translational Sciences and NIH UL1TR000002. Sina Farsiu: NIH P30 EY005722. Ronald P. Danis: Research to Prevent Blindness, Inc. (New York, NY) Glenn Yiu: by NIH K08 EY026101, the E. Matilda Ziegler Foundation for the Blind (New York, NY), Barr Foundation for Retinal Research (previously Northbrook, Illinois now Columbia, MD), Alcon Research Institute (Fort Worth, TX), and the ARVO Foundation (Rockville, MD)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5969. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alex Willoughby, Vivian Vuong, David Cunefare, Sina Farsiu, Glenn Noronha, Ronald P Danis, Glenn Yiu; Choroidal Changes after Suprachoroidal Injection of CLS-TA, Triamcinolone Acetonide Injectable Suspension, in Eyes with Macular Edema Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5969.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate choroidal and suprachoroidal changes following suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, in eyes with macular edema due to retinal vein occlusion (RVO).

Methods : Enhanced depth imaging optical coherence tomography (EDI-OCT) images were analyzed from 38 eyes of 38 treatment naïve patients with macular edema due to RVO, enrolled in the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received at baseline either a suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA) with an intravitreal injection of aflibercept (combination arm) or only an intravitreal injection of aflibercept (monotherapy arm) followed by monthly intravitreal aflibercept injections in both arms based on pro re nata (PRN) criteria.

Results : Macular choroidal thickness measured to the outer choroidal vessel lumen (vascular choroidal thickness, VCT), outer choroid stroma (stromal choroidal thickness, SCT), or inner scleral border (total choroidal thickness, TCT) showed no significant changes over 3 months in both study arms (P = 0.231-0.342). Eyes that received combination therapy showed a trend toward thickening of the suprachoroidal space (SCS) compared with monotherapy alone (13.4 µm vs 5.3 µm at 3 months; P=0.077). In the 15 eyes that demonstrated a visible SCS at baseline, the SCS expanded significantly after suprachoroidal CLS-TA injection (16.2 mm to 27.8 mm at 3 months; P=0.033).

Conclusions : Suprachoroidal injection of CLS-TA does not alter choroidal thickness in eyes with macular edema due to RVO, but may result in expansion of the SCS.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×